DK2332533T3 - Cannabinoidholdige planteekstrakter som neurobeskyttelsesmidler - Google Patents

Cannabinoidholdige planteekstrakter som neurobeskyttelsesmidler Download PDF

Info

Publication number
DK2332533T3
DK2332533T3 DK10189019.2T DK10189019T DK2332533T3 DK 2332533 T3 DK2332533 T3 DK 2332533T3 DK 10189019 T DK10189019 T DK 10189019T DK 2332533 T3 DK2332533 T3 DK 2332533T3
Authority
DK
Denmark
Prior art keywords
cannabinoid
thc
cbd
cannabinoids
concentration
Prior art date
Application number
DK10189019.2T
Other languages
English (en)
Inventor
Geoffrey Guy
Bettina Platt
Original Assignee
Gw Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36010529&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2332533(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gw Pharma Ltd filed Critical Gw Pharma Ltd
Application granted granted Critical
Publication of DK2332533T3 publication Critical patent/DK2332533T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Claims (1)

1. Planteekstrakt af Cannabis sativa L, der enten omfatter: a) et ekstrakt, hvor et større cannabinoid er tetrahydrocannabinol (THC) og ekstraktet omfatter (vægt/vægt ekstrakt) i) 63,0 - 78,0 % THC, 0,1 - 2,5 % cannabidiol, 1,0 - 2,0 % cannabigerol, 0,8 - 2,2 % cannabichromen, 0,4 - 1,0 % tetrahydrocannabivarin, og < 2,0 % tetrahydrocannabinolsyre og ii) < 6,0 % terpener indbefattende monoterpener; di/tri-terpener; sesquiterpener; og andre terpener og 6,3 - 26,7 % steroler; triglycerider; alkaner; squalen; tocopherol og carotenoider eller b) et ekstrakt, hvor et større cannabinoid er cannabidiol (CBD) og ekstraktet omfatter (vægt/vægt ekstrakt) i) 57,0 - 72,0 % CBD, 2,0 - 6,5 % THC, 0,8 - 6,5 % cannabigerol, 3,0 - 6,5 % cannabichromen, 1,0 - 2,0 % cannabidivarin og < 2,0 % cannabidiolsyre og ii) <5,8% terpener indbefattende monoterpener; di/tri-terpener; sesquiterpener og andre terpener, og 1,7 - 28,4 % steroler; triglycerider; alkaner; squalen; tocopherol og carotenoider; og hvor forholdet mellem den cannabinoidholdige fraktion (i) og den ikke-cannabinoidholdige fraktion (ii) er mellem 60:40 og 90:10 af det totale ekstrakt.
DK10189019.2T 2006-01-18 2007-01-17 Cannabinoidholdige planteekstrakter som neurobeskyttelsesmidler DK2332533T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0601013A GB2434312B (en) 2006-01-18 2006-01-18 Cannabinoid-containing plant extracts as neuroprotective agents
EP07704916.1A EP1976506B1 (en) 2006-01-18 2007-01-17 Cannabinoid-containing plant extracts as neuroprotective agents

Publications (1)

Publication Number Publication Date
DK2332533T3 true DK2332533T3 (da) 2018-12-10

Family

ID=36010529

Family Applications (2)

Application Number Title Priority Date Filing Date
DK07704916.1T DK1976506T3 (da) 2006-01-18 2007-01-17 Cannabinoid-holdige planteekstrakter som neuroprotektorer
DK10189019.2T DK2332533T3 (da) 2006-01-18 2007-01-17 Cannabinoidholdige planteekstrakter som neurobeskyttelsesmidler

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK07704916.1T DK1976506T3 (da) 2006-01-18 2007-01-17 Cannabinoid-holdige planteekstrakter som neuroprotektorer

Country Status (13)

Country Link
US (2) US8673368B2 (da)
EP (2) EP2332533B1 (da)
CA (1) CA2636634C (da)
CY (2) CY1121136T1 (da)
DK (2) DK1976506T3 (da)
ES (2) ES2746973T3 (da)
GB (1) GB2434312B (da)
HU (2) HUE041959T2 (da)
LT (2) LT2332533T (da)
PL (2) PL2332533T3 (da)
PT (2) PT1976506T (da)
SI (2) SI2332533T1 (da)
WO (1) WO2007083098A1 (da)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2434312B (en) 2006-01-18 2011-06-29 Gw Pharma Ltd Cannabinoid-containing plant extracts as neuroprotective agents
GB2450753B (en) * 2007-07-06 2012-07-18 Gw Pharma Ltd New Pharmaceutical formulation
GB2451254A (en) * 2007-07-24 2009-01-28 Gw Pharma Ltd Cannabidiol for use in the treatment of neurodegenerative conditions
US20110257256A1 (en) * 2008-07-31 2011-10-20 Bionoria Research Gmbh Cannabinoids for use in treating or preventing cognitive impairment and dementia
GB2471523A (en) 2009-07-03 2011-01-05 Gw Pharma Ltd Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy
GB2478595B (en) * 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
GB2479153B (en) * 2010-03-30 2014-03-19 Gw Pharma Ltd The phytocannabinoid cannabidivarin (CBDV) for use in the treatment of epilepsy
TWI583374B (zh) 2010-03-30 2017-05-21 Ｇｗ伐瑪有限公司 使用植物大麻素次大麻二酚（ｃｂｄｖ）來治療癲癇之用途
GB2487183B (en) * 2011-01-04 2018-10-03 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy
US8445034B1 (en) 2010-11-02 2013-05-21 Albert L Coles, Jr. Systems and methods for producing organic cannabis tincture
GB2487712B (en) 2011-01-04 2015-10-28 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
GB201111261D0 (en) 2011-07-01 2011-08-17 Gw Pharma Ltd Cannabinoids for use in the treatment of neuro-degenerative diseases or disorders
GB2514054A (en) 2011-09-29 2014-11-12 Gw Pharma Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
GB2504263B (en) 2012-06-08 2015-09-16 Gw Pharma Ltd Synergistic therapies for neuroprotection
CA2895805A1 (en) 2012-12-18 2014-06-26 Kotzker Consulting Llc Use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity
CA3012383C (en) 2013-02-28 2021-03-02 Teewinot Technologies Limited Biosynthesis of cannabinoids
EP2968259B1 (en) * 2013-03-14 2022-09-14 SC Laboratories Inc. Bioactive concentrates and uses thereof
US10774288B2 (en) 2013-09-18 2020-09-15 The Werc Shop, LLC Terpene-based compositions, processes, methodologies for creation and products thereby
US9220294B2 (en) 2014-02-11 2015-12-29 Timothy McCullough Methods and devices using cannabis vapors
US10821240B2 (en) 2014-02-11 2020-11-03 Vapor Cartridge Technology Llc Methods and drug delivery devices using cannabis
US9380813B2 (en) 2014-02-11 2016-07-05 Timothy McCullough Drug delivery system and method
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2527599A (en) 2014-06-27 2015-12-30 Gw Pharma Ltd Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy
CA2990071C (en) 2014-07-14 2023-01-24 Librede Inc. Production of cannabigerolic acid
US11293038B2 (en) 2014-07-14 2022-04-05 Librede Inc. Production of cannabinoids in yeast
CN109593651A (zh) 2014-08-25 2019-04-09 蒂威诺特科技有限公司 用于大麻素化合物的同时生产的设备和方法
GB2531278A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531281A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
BR122021018502B1 (pt) 2014-10-21 2022-05-03 United Cannabis Corp Formulação de canabinoide líquida
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal
GB2541191A (en) 2015-08-10 2017-02-15 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
AU2016337507B2 (en) * 2015-10-16 2019-09-19 Impact Biosciences Corp. Methods and compositions for treating traumatic brain injury
EP3383387B1 (en) * 2015-12-05 2025-11-05 Canna-B Cure Ltd Veterinary composition comprising cbd and/or thc for use in the treatment of stress in bees
US11172698B1 (en) 2016-02-08 2021-11-16 Jeff Nordahl Pasteurized juice formed from raw cannabis
US11191794B1 (en) 2016-02-08 2021-12-07 Jeff Nordahl Packaged hemp products formed from raw cannabis
US9956174B1 (en) 2016-02-08 2018-05-01 Jeff Nordahl Packaged frozen cubes of cannabis juice purée with added decarboxylated cannabis material
US11779622B1 (en) 2016-02-08 2023-10-10 Jeff Nordahl Packaged raw cannabis powder
PT3429580T (pt) * 2016-03-16 2025-08-12 Buzzelet Development And Technologies Ltd Composição de canabinoides enriquecida em terpenos
GB2548873B (en) 2016-03-31 2020-12-02 Gw Res Ltd Use of Cannabidiol in the Treatment of SturgeWeber Syndrome
GB2549278B (en) * 2016-04-11 2021-02-17 Gw Res Ltd Use of cannabidivarin in the treatment of autism spectrum disorder
GB2549277B (en) 2016-04-11 2021-02-17 Gw Res Ltd Cannabidiolic Acid for use in the Treatment of Autism Spectrum Disorder
US10499584B2 (en) 2016-05-27 2019-12-10 New West Genetics Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles
US9717683B1 (en) 2016-06-29 2017-08-01 Ep Pharma, Llc Low-temperature inhalation administration of cannabinoid entities
WO2018000094A1 (en) 2016-06-29 2018-01-04 CannScience Innovations Inc. Decarboxylated cannabis resins, uses thereof and methods of making same
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
GB2551986A (en) 2016-07-01 2018-01-10 Gw Res Ltd Parenteral formulations
GB2553139A (en) 2016-08-25 2018-02-28 Gw Res Ltd Use of cannabinoids in the treatment of multiple myeloma
CA3077624A1 (en) * 2016-10-01 2018-04-05 James Smeeding Pharmaceutical compositions comprising a statin and a cannabinoid and uses thereof
CN109963595B (zh) * 2016-10-11 2023-02-03 Gbs全球生物制药公司 用于治疗神经退行性疾病的含有大麻素的复合混合物
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
GB2557921A (en) 2016-12-16 2018-07-04 Gw Res Ltd Use of cannabinoids in the treatment of angelman syndrome
US10857107B2 (en) 2017-02-01 2020-12-08 Gbs Global Biopharma, Inc. Cannabinoid-containing complex mixtures for the treatment of mast cell-associated or basophil-mediated inflammatory disorders
US20190374502A1 (en) * 2017-02-09 2019-12-12 Bodhi Research & Development Inc. Cannabinoid-Containing Fatty Acid Formulations for Treating Disorders of the Nervous System
GB2559774B (en) 2017-02-17 2021-09-29 Gw Res Ltd Oral cannabinoid formulations
GB2560019A (en) 2017-02-27 2018-08-29 Gw Res Ltd Use of cannabinoids in the treatment of leukaemia
BR112019019966A2 (pt) 2017-03-24 2020-04-28 Trait Biosciences Inc biossíntese in vivo de alto nível e isolamento de canabinoides solúveis em água em sistemas de plantas
CN107137605A (zh) * 2017-03-27 2017-09-08 昭通天麻产业开发有限公司 一种由乌天麻提取物和植物大麻提取物及口服载体组成的组合物
WO2018205038A1 (en) * 2017-05-12 2018-11-15 Tetra Bio-Pharma Inc. Compositions comprising cannabinoids and terpenes useful in the treatment of cancer and vascular ocular disorders via inhibition of hedgehog signalling
GB2564383B (en) 2017-06-23 2021-04-21 Gw Res Ltd Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex
US11905543B2 (en) 2017-07-11 2024-02-20 Trait Biosceinces, Inc. In vivo generation of water-soluble acetylated cannabinoid glycoside compounds in plant cell suspension cultures
CN111465700A (zh) 2017-07-11 2020-07-28 特征生物科学公司 在酵母和植物细胞悬浮培养物中产生水溶性大麻素化合物和材料组合物
US11946059B2 (en) 2017-07-11 2024-04-02 Trait Biosciences, Inc. In vivo generation of water-soluble cannabinoids in plant cell suspension cultures
GB2564459B (en) 2017-07-12 2022-03-09 Gw Res Ltd Use of cannabinoids in the treatment of a neurodegenerative disease or disorder
US10272360B2 (en) 2017-08-05 2019-04-30 Priya Naturals, Inc. Phytochemical extraction system and methods to extract phytochemicals from plants including plants of the family Cannabaceae sensu stricto
EP3687527A4 (en) * 2017-09-25 2021-05-26 Canopy Health Innovations COMPOSITIONS OF CANNABIDIOL, TETRAHYDROCANNABINOL, TERPENS AND FLAVONOIDS AND THEIR USES FOR TREATMENT OF INSOMNIA
US10307392B2 (en) * 2017-10-21 2019-06-04 Alexander Kariman Compound and method for treatment of diseases and disorders
US20190183849A1 (en) * 2017-10-21 2019-06-20 Alexander Kariman Compound and method for treatment of diseases and disorders
GB2568929A (en) 2017-12-01 2019-06-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
US10722545B2 (en) 2018-01-01 2020-07-28 Alexander Kariman Compound and method for treatment of movement disorders
GB2569961B (en) 2018-01-03 2021-12-22 Gw Res Ltd Pharmaceutical
CA3089994A1 (en) 2018-01-31 2019-08-08 Canopy Holdings, LLC Hemp powder
EP3773527A4 (en) * 2018-03-30 2022-04-13 India Globalization Capital, Inc. METHOD AND COMPOSITION FOR THE TREATMENT OF CNS DISEASES
GB201806953D0 (en) 2018-04-27 2018-06-13 Gw Res Ltd Cannabidiol Preparations
US20200035118A1 (en) 2018-07-27 2020-01-30 Joseph Pandolfino Methods and products to facilitate smokers switching to a tobacco heating product or e-cigarettes
US20220304963A1 (en) * 2018-07-27 2022-09-29 Basil Shaaban Composition having an optimized fatty acid excipient profile
US10897925B2 (en) 2018-07-27 2021-01-26 Joseph Pandolfino Articles and formulations for smoking products and vaporizers
WO2020077153A1 (en) 2018-10-10 2020-04-16 Canopy Holdings, LLC Synthesis of cannabigerol
BR112021009021A2 (pt) * 2018-11-09 2021-10-26 Agriculture Victoria Services Pty Ltd Plantas de cannabis com um perfil canabinoide enriquecido de canabidiol e delta-9-tetra-hidrocanabinol
CA3061143A1 (en) * 2018-11-09 2020-05-09 Cronos Group Inc. Liquid composition for an electronic vapor device
US12220396B2 (en) 2019-05-03 2025-02-11 Zyus Life Sciences Inc. Formulation for pain management
ES2986503T3 (es) 2019-05-03 2024-11-11 Zyus Life Sciences Inc Formulación para el manejo del dolor que comprende tetrahidrocannabinol (THC), cannabicromeno (CBC) y cannabidiol (CBD) en una proporción determinada
US12178797B2 (en) 2019-05-03 2024-12-31 Zyus Life Sciences Inc. Formulation for pain management
GB2584341B (en) 2019-05-31 2023-03-01 Gw Res Ltd Cannabinoid formulations
US12557843B2 (en) * 2019-07-15 2026-02-24 Raymond Louis Larson Other than cannabinoids, flavonoids, and terpenes
CA3154135A1 (en) 2019-09-16 2021-03-25 Vapor Cartridge Technology Llc Drug delivery system with stackable substrates
US12409131B2 (en) 2019-10-03 2025-09-09 Pike Therapeutics Usa, Inc. Transdermal delivery of dronabinol
AU2020358869A1 (en) 2019-10-03 2022-04-14 Pike Therapeutics Usa, Inc. Transdermal delivery of dronabinol
US12016829B2 (en) 2019-10-11 2024-06-25 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
EP4041209A4 (en) 2019-10-11 2024-01-24 Pike Therapeutics, Inc. TRANSDERMAL COMPOSITIONS COMPRISING CANNABIDIOL (CBD) FOR USE IN THE TREATMENT OF EPILEPTIC DISORDERS
US12268699B2 (en) 2019-10-14 2025-04-08 Pike Therapeutics Inc. Transdermal delivery of tetrahydrocannabinol
US12121617B2 (en) 2019-10-14 2024-10-22 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
CA3155181A1 (en) 2019-10-14 2021-04-22 Pike Therapeutics, Inc., 1219014 B.C. Ltd. Transdermal delivery of cannabidiol
GB202002754D0 (en) 2020-02-27 2020-04-15 Gw Res Ltd Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
CN115551592A (zh) * 2020-03-17 2022-12-30 陶里加科学股份有限公司 药用大麻素组合物、制造方法和治疗方法
US11160757B1 (en) 2020-10-12 2021-11-02 GW Research Limited pH dependent release coated microparticle cannabinoid formulations
KR20220084761A (ko) 2020-12-14 2022-06-21 강원대학교산학협력단 헴프 껍질 추출물을 포함하는 인지기능 개선용 조성물
CN113368086B (zh) * 2021-08-11 2021-12-03 龙麻(上海)医药研发有限责任公司 一种大麻素组合物及其在制备治疗帕金森、阿尔茨海默等神经退行性疾病的药物中的应用
US12036228B2 (en) 2022-04-12 2024-07-16 Shackelford Pharma Inc. Treatment of seizure disorders
AU2023321655A1 (en) 2022-08-12 2025-02-13 Jazz Pharmaceuticals Research Uk Limited Oral solid dosage forms comprising cannabinoids
WO2024148117A2 (en) * 2023-01-04 2024-07-11 Florascience Inc. Methods of treating neurodegenerative diseases or conditions
WO2025090587A1 (en) 2023-10-23 2025-05-01 Inmed Pharmaceuticals Inc. Cannabinoids compounds and their use in the treatment of neuronal disorders
WO2025172553A1 (en) 2024-02-14 2025-08-21 Jazz Pharmaceuticals Research Uk Limited Oral solid dosage forms comprising cannabinoids
WO2025234537A1 (ko) * 2024-05-07 2025-11-13 주식회사 퓨처에프바이오텍 대마 종자 발효물을 포함하는 비만 또는 인지기능 개선용 조성물

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2337633B (en) 1998-05-20 2003-04-02 Mitel Corp Method of forming capacitors in a semiconductor device
DE10051427C1 (de) 2000-10-17 2002-06-13 Adam Mueller Verfahren zur Herstellung eines Tetrahydrocannabinol- und Cannabidiol-haltigen Extraktes aus Cannabis-Pflanzenmaterial sowie Cannabis-Extrakte
DK1361864T3 (da) 2001-02-14 2014-03-03 Gw Pharma Ltd Flyldende sprayformuleringer til bukkal indgivelse af cannabinoider
CH695661A5 (de) 2001-03-06 2006-07-31 Forsch Hiscia Ver Fuer Krebsfo Pharmazeutische Zusammensetzung.
GB2377218A (en) 2001-05-04 2003-01-08 Gw Pharmaceuticals Ltd Process and apparatus for extraction of active substances and enriched extracts from natural products
GB2381450B (en) * 2001-10-31 2006-05-31 Gw Pharma Ltd Compositions for administration of natural or synthetic cannabinoids by vaporisation
DE10226494A1 (de) * 2002-06-14 2004-01-08 Lts Lohmann Therapie-Systeme Ag Filmförmige mucoadhäsive Darreichungsformen zur Verabreichung von Cannabis-Wirkstoffen
ATE533472T1 (de) * 2002-08-14 2011-12-15 Gw Pharma Ltd Flüssige cannabinoid-formulierungen zur verabreichung an die schleimhäute
GB2392093B (en) * 2002-08-14 2006-03-08 Gw Pharma Ltd Pharmaceutical formulations
US6946150B2 (en) * 2002-08-14 2005-09-20 Gw Pharma Limited Pharmaceutical formulation
GB2391865B (en) 2002-08-14 2005-06-01 Gw Pharma Ltd Improvements in the extraction of pharmaceutically active components from plant materials
WO2004100893A2 (en) * 2003-05-12 2004-11-25 Indevus Pharmaceuticals, Inc. Methods for treatment of inflammatory diseases using ct-3 or analogs thereof
AU2005305675B2 (en) 2004-11-16 2012-12-13 Jazz Pharmaceuticals Operations Uk Limited New use for cannabinoid
GB2434312B (en) 2006-01-18 2011-06-29 Gw Pharma Ltd Cannabinoid-containing plant extracts as neuroprotective agents
WO2008024490A2 (en) 2006-08-24 2008-02-28 Theraquest Biosciences, Inc. Oral pharmaceutical formulations of abuse deterrent cannabinoids and method of use
GB2450493A (en) 2007-06-25 2008-12-31 Gw Pharma Ltd Cannabigerol for use in treatment of diseases benefiting from agonism of CB1 and CB2 cannabinoid receptors
GB2479153B (en) 2010-03-30 2014-03-19 Gw Pharma Ltd The phytocannabinoid cannabidivarin (CBDV) for use in the treatment of epilepsy
GB201111261D0 (en) 2011-07-01 2011-08-17 Gw Pharma Ltd Cannabinoids for use in the treatment of neuro-degenerative diseases or disorders

Also Published As

Publication number Publication date
EP1976506A1 (en) 2008-10-08
US9205063B2 (en) 2015-12-08
EP2332533A1 (en) 2011-06-15
LT2332533T (lt) 2018-12-27
HUE046388T2 (hu) 2020-03-30
HUE041959T2 (hu) 2019-06-28
DK1976506T3 (da) 2019-10-07
GB0601013D0 (en) 2006-03-01
PL2332533T3 (pl) 2019-02-28
CA2636634C (en) 2017-07-11
CA2636634A1 (en) 2007-07-26
ES2698370T3 (es) 2019-02-04
GB2434312B (en) 2011-06-29
US8673368B2 (en) 2014-03-18
EP2332533B1 (en) 2018-08-22
WO2007083098A1 (en) 2007-07-26
PT1976506T (pt) 2019-10-15
US20100239693A1 (en) 2010-09-23
EP1976506B1 (en) 2019-06-26
GB2434312A (en) 2007-07-25
SI2332533T1 (sl) 2019-02-28
ES2746973T3 (es) 2020-03-09
PT2332533T (pt) 2018-11-29
CY1122076T1 (el) 2020-11-25
LT1976506T (lt) 2019-10-10
PL1976506T3 (pl) 2020-01-31
SI1976506T1 (sl) 2019-11-29
CY1121136T1 (el) 2020-05-29
US20140377382A1 (en) 2014-12-25

Similar Documents

Publication Publication Date Title
DK2332533T3 (da) Cannabinoidholdige planteekstrakter som neurobeskyttelsesmidler
US10258580B2 (en) Cannabinoids for use in the treatment of neurodegenerative diseases or disorders
Ki et al. JNK and p38 MAPK regulate oxidative stress and the inflammatory response in chlorpyrifos-induced apoptosis
Gerszon et al. Antioxidant properties of resveratrol and its protective effects in neurodegenerative diseases
Chen et al. Salidroside attenuates glutamate-induced apoptotic cell death in primary cultured hippocampal neurons of rats
Yin et al. Effects of Epigallocatechin-3-gallate on lead-induced oxidative damage
Lv et al. GLP-1 analogue liraglutide attenuates CIH-induced cognitive deficits by inhibiting oxidative stress, neuroinflammation, and apoptosis via the Nrf2/HO-1 and MAPK/NF-κB signaling pathways
US20130245110A1 (en) Use for cannabinoids
Jiao et al. Tetrahydroxy stilbene glycoside (TSG) antagonizes Aβ-induced hippocampal neuron injury by suppressing mitochondrial dysfunction via Nrf2-dependent HO-1 pathway
Ding et al. Proanthocyanidins protect against early diabetic peripheral neuropathy by modulating endoplasmic reticulum stress
KR20100113099A (ko) 항정신병 약물과 조합된 카나비노이드의 용도
Ogawa et al. The protective effects of bilberry and lingonberry extracts against UV light-induced retinal photoreceptor cell damage in vitro
Novelli et al. St. John’s wort extract and hyperforin inhibit multiple phosphorylation steps of cytokine signaling and prevent inflammatory and apoptotic gene induction in pancreatic β cells
Siqueira et al. Neuroprotective effects of Ptychopetalum olacoides Bentham (Olacaceae) on oxygen and glucose deprivation induced damage in rat hippocampal slices
Salama et al. Influence of chrysin on D‐galactose induced‐aging in mice: Up regulation of AMP kinase/liver kinase B1/peroxisome proliferator‐activated receptor‐γ coactivator 1‐α signaling pathway
Mohammadipour A focus on natural products for preventing and cure of mitochondrial dysfunction in Parkinson’s disease
Kumar et al. Antidiabetic activity of alcoholic root extract of Caesalpinia digyna in streptozotocin-nicotinamide induced diabetic rats
Dagon et al. The synthetic cannabinoid HU-210 attenuates neural damage in diabetic mice and hyperglycemic pheochromocytoma PC12 cells
HK1158956B (en) Cannabinoid-containing plant extracts as neuroprotective agents
HK1158956A (en) Cannabinoid-containing plant extracts as neuroprotective agents
Wankhede et al. Stigmasterol Alleviates Levodopa-Induced Dyskinesia in 6-OHDA-Induced Parkinsonian Rats
Al-Nefeiy et al. A comparative Study of the Effects of virgin coconut oil and vitamin d on Alzheimer’s disease induced by aluminium chloride in male albino rats hippocampus
AU2021107253A4 (en) A composition and uses thereof
Kaya et al. A review on the effects of Cannabis sativa L. on human cognition
Marzouk The Effect of Cannabinoids and Terpenes on the Activation of HMC3 Microglial Cells